Ashland's nutraceuticals business supplies a broad portfolio of active ingredients and formulation aids to nutritional product companies
iSolveSM information on demand is the result of our focus on customer relationship
Multi-ethnic innovation helps all complexions appear clearer and more uniform
This four-day course is designed for professionals in the pharmaceutical, nutraceutical, and related industries
This innovative product eliminates two manufacturing steps and simplifies equipment setup
Gafchromic films support patient care in oncology
Ashland’s pharmaceutical business is well known for acetylenics, cellulosics, and film coatings
The voluntary program is the first time the FDA will allow excipient manufacturers to obtain review of certain novel excipients prior to their use in drug formulations.
The need for hot-melt extrusion (HME) polymers is expected to grow as the pharma industry moves to implement more continuous and sustainable processes.
The capital expansion program commenced in June 2022 and is expected to complete in 2024
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)